Latest Period
Q1 2026
Security Snapshot
Pharming Group N.V. - Ordinary Shares / American Depositary Shares (PHAR) Institutional Ownership
CUSIP: 71716E105
13F Institutional Holders and Ownership History from Q2 2020 to Q2 2026
Institutions Reporting
12
Shares (Excl. Options)
84,968
Price
$16.64
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares / American Depositary Shares
- Symbol
- PHAR on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 84,968
- Total 13F value
- $1,413,868
- Portfolio coverage rank
- 0%
- Share change
- -54,214
- Value change
- -$923,132
- Number of holders
- 12
- Shares outstanding
- 705,983,417
- SEC-reported price per share
- $13.89
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PHAR - Pharming Group N.V. - Ordinary Shares / American Depositary Shares is tracked under CUSIP 71716E105.
- 12 institutions reported positions in Q1 2026.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 12 to 5 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $1,413,868 to $897,098.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 12 institutions filings for Q1 2026.
Security key
71716E105
Latest holder period
Q1 2026
13F holders
12
13D/G owners
1
CIK / CUSIP context first
Open Q1 2026 holders
PHAR full holder history
Pharming Group N.V. SEC filings
Pharming Group N.V. company facts
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 71716E105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
1
Security
PHAR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| MORGAN STANLEY | 1.2% | $70,739,538 | 8,471,801 | Morgan Stanley | 31 Mar 2025 |
As of 31 Mar 2026, 12 institutional investors reported holding 84,968 shares of Pharming Group N.V. - Ordinary Shares / American Depositary Shares (PHAR). This represents 0.01% of the company’s total 705,983,417 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Latest
Q1 2026
Rows shown
1-24 of 24
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 64,882 | $897,098 | +$115,009 | $13.89 | 5 |
| 2026 Q1 | 84,968 | $1,413,868 | -$923,132 | $16.64 | 12 |
| 2025 Q4 | 140,452 | $2,481,786 | +$1,200,542 | $17.67 | 10 |
| 2025 Q3 | 59,127 | $857,346 | +$1,902 | $14.50 | 8 |
| 2025 Q2 | 58,026 | $620,298 | +$75,322 | $10.69 | 3 |
| 2025 Q1 | 51,003 | $426,701 | -$1,676 | $8.37 | 3 |
| 2024 Q4 | 51,101 | $514,333 | +$64,544 | $10.07 | 5 |
| 2024 Q3 | 44,747 | $369,164 | +$138,704 | $8.25 | 4 |
| 2024 Q2 | 27,592 | $230,393 | +$58,701 | $8.35 | 4 |
| 2024 Q1 | 20,562 | $215,901 | +$546 | $10.50 | 3 |
| 2023 Q4 | 20,510 | $234,429 | -$263,673 | $11.43 | 2 |
| 2023 Q3 | 25,930 | $295,602 | +$267,102 | $11.40 | 3 |
| 2023 Q2 | 24,960 | $290,784 | -$11,894 | $11.65 | 2 |
| 2023 Q1 | 25,841 | $295,644 | -$51,546 | $13.50 | 3 |
| 2022 Q4 | 29,510 | $325,137 | +$49,840 | $11.03 | 3 |
| 2022 Q3 | 24,984 | $245,000 | +$44,126 | $9.78 | 3 |
| 2022 Q2 | 20,472 | $180,000 | -$1,433 | $8.80 | 3 |
| 2022 Q1 | 20,586 | $184,000 | +$17,832 | $8.88 | 4 |
| 2021 Q4 | 18,628 | $166,000 | -$77,219 | $8.92 | 3 |
| 2021 Q3 | 26,355 | $249,000 | -$1,873,745 | $9.46 | 4 |
| 2021 Q2 | 198,407 | $2,237,000 | +$413 | $11.27 | 7 |
| 2021 Q1 | 192,149 | $2,465,000 | -$21,866,828 | $12.83 | 3 |
| 2020 Q4 | 1,896,857 | $2,963,000 | +$2,963,000 | $8.42 | 2 |
| 2020 Q2 | 16,500 | $145,000 | $8.79 | 1 |